This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.
Science advances · 2026
A Neuronal Cell Line Model for Studying Camel Prions.
Pathogens (Basel, Switzerland) · 2026
Prion shedding is reduced by chronic wasting disease vaccination.
PLoS pathogens · 2026
Latest funding
- $1,025,100
Mechanisms of endo-lysosomal dysfunction in neurodegenerative protein misfolding diseases
CIHR · 2026 · Nominated PI
- $137,553
Spatial transcriptomics in prion research
NSERC · 2025 · Principal investigator
- $875,925
Peptide aptamers interacting with the cellular prion protein for treatment of neurodegenerative diseases
CIHR · 2023 · Nominated PI
47 publications.
Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.
Hannaoui S, Pritzkow S, Jürgens-Wemheuer WM, Motzkus D, Wälzlein JH, Schwenke KA, Cheng YC, Ahmed Hassan H, Zemlyankina I, Drever K, Beekes M, Schulz-Schaeffer WJ, Stahl-Hennig C, Gilch S, Soto C, Czub S, Schätzl HM
A Neuronal Cell Line Model for Studying Camel Prions.
Abdulrahman B, Rahimi Aqdam S, Mosca M, Ahmed-Hassan H, Razcon-Echeagaray M, Popa L, Gilch S, Babelhadj B, Vaccari G, Schätzl HM
Prion shedding is reduced by chronic wasting disease vaccination.
Ahmed-Hassan H, Abdelaziz D, Cheng YC, Low K, Phan S, Kruger B, Dalton CS, Kaczmarczyk L, Jackson WS, Gilch S, Schätzl HM
Prion shedding is reduced by chronic wasting disease vaccination.
Ahmed-Hassan H, Abdelaziz D, Cheng YC, Low K, Phan S, Kruger B, Dalton CS, Kaczmarczyk L, Jackson WS, Gilch S, Schätzl HM
Contrasting roles of autophagy in cellular prion infection.
Abdulrahman B, Heiseke A, Aguib Y, Lu L, Abdelaziz D, Ansari M, Thapa S, Taguchi Y, Gilch S, Schätzl HM
Genetic Variation and Strain Dynamics in Chronic Wasting Disease.
Zemlyankina I, Razcon-Echeagaray M, Yilmaz G, Gregg KB, Gilch S, Hannaoui S
Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model by regulating brain cholesterol metabolism.
Ali T, Cashion J, Hannaoui S, Ahmed-Hassan H, Schatzl H, Gilch S
Lack of cellular prion protein causes Amyloid β accumulation, increased extracellular vesicle abundance, and changes to exosome biogenesis proteins.
Johansson L, Reyes JF, Ali T, Schätzl H, Gilch S, Hallbeck M
Extraneural infection route restricts prion conformational variability and attenuates the impact of quaternary structure on infectivity.
Chang SC, Arifin MI, Tahir W, McDonald KJ, Zeng D, Schatzl HM, Hannaoui S, Gilch S
Norwegian moose CWD induces clinical disease and neuroinvasion in gene-targeted mice expressing cervid S138N prion protein.
Arifin MI, Hannaoui S, Ng RA, Zeng D, Zemlyankina I, Ahmed-Hassan H, Schatzl HM, Kaczmarczyk L, Jackson WS, Benestad SL, Gilch S
Mechanisms of endo-lysosomal dysfunction in neurodegenerative protein misfolding diseases
Principal investigators: Gilch, Sabine
Keywords: Cell Culture; Cholesterol Metabolism; Creutzfeldt-Jakob Disease; Endocytic Vesicle Trafficking; Mouse Models; Neurodegenerative Diseases; Primary Neurons; Prions; Proteomics
Spatial transcriptomics in prion research
Principal investigators: Gilch, Sabine
Keywords: spatial transcriptomics; prions; chronic wasting disease; neurodegeneration; cwd vaccine; gene-targeted mouse models; immunohistochemistry; prion strain; protein misfolding disease
Peptide aptamers interacting with the cellular prion protein for treatment of neurodegenerative diseases
Principal investigators: Gilch, Sabine
Keywords: Alzheimer'S Disease; Cell Culture; Cellular Prion Protein; Mouse Models; Neurodegeneration; Peptide Aptamers; Prion Disease
Peptide aptamers interacting with the cellular prion protein for treatment of neurodegenerative diseases
Principal investigators: Gilch, Sabine
Keywords: Alzheimer'S Disease; Cellular Prion Protein; Prion Disease
Innovation and interdisciplinary research to understand the causes and mitigate consequences of environmental change in the Boreal Plains
Principal investigators: McLoughlin, Philip
A comprehensive approach to halt chronic wasting disease transmission
Principal investigators: Gilch, Sabine S
Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
Principal investigators: Ali, Tahir
Keywords: Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative Diseases; Neurosciences; Treatment Of Human Prion Disease
Building capacity for in vitro prion amplification
Principal investigators: Gilch, Sabine
Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases
Principal investigators: Ali, Tahir
Keywords: Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative Diseases; Neurosciences; Treatment Of Human Prion Diseases
Targeting brain cholesterol homeostasis to counteract prion diseases
Principal investigators: Gilch, Sabine
Keywords: Cell Biology Of Prion Infection; Cholesterol Metabolism; Endocytic Vesicle Trafficking; Mouse Models Of Prion Disease; Neurodegeneration; Prion Disease; Treatment Of Prion Disease
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biochemistry
- Genome Sciences Centre
- Medicine
- Biochemistry and Molecular Biology
- Other
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.